Laboratorios Richmond SACIF (RICH) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Laboratorios Richmond SACIF stock ARS 1,496, price ARS 1,390, upside +7.6%, quality 24 out of 100. Rating: fairly valued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 212.00 ARS – 2,180 ARS · fair‑value band 770.12 ARS – 1,944 ARS · the 1,390 ARS price screens below the 1,496 ARS fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Laboratorios Richmond SACIF in your weekly email
Every Wednesday you see whether Laboratorios Richmond SACIF is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Laboratorios Richmond S.A.C.I.F., together with its subsidiaries, develops, manufactures, and sells pharmaceutical products in Latin America, Africa, Asia, and the Middle East.
Show moreShow less
It offers antiretroviral drugs for the treatment of human immunodeficiency virus; oncology and oncohematology drugs; cardiometabolism drugs, including antihypertensive, hypocholesterolemic, platelet antiaggregants, and hypoglycemic drugs; and neurological and psychiatric drugs, such as analgesics, antipsychotics, antidepressants, anti-dementia, antiepileptics, and hypnotic drugs, as well as drugs for the treatment of multiple sclerosis.
The company was incorporated in 1959 and is headquartered in Buenos Aires, Argentina.
Stock analysis
Laboratorios Richmond SACIF (RICH) currently trades at 1,390 ARS, while our model-based Fair Value estimate is 1,496 ARS, so the stock looks roughly fairly valued today (gap 7.1%).
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 2,723 ARS per share, and 6 of the 14 models we run sit above the 1,390 ARS price.
Bear case: the Dividend Discount group reads lowest at 226.24 ARS, and 8 of the 14 models stay below the price. Data coverage for this calculation is low.
Scenario range: 770.12 ARS (bear) to 1,944 ARS (bull), the price of 1,390 ARS sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 24/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Laboratorios Richmond SACIF reported revenue of 127B ARS in FY2025 versus 16.6B ARS in FY2021, a compound +66.2%/yr. Reported net income was 3.1B ARS in FY2025, compounding +51.2%/yr from FY2021.
Key figures
Market cap 112B ARS (≈ $72.7M) Micro · P/E ratio 7.3 · P/S ratio 0.98 · EPS (TTM) 175.64 ARS · Net margin 11.0% · Return on equity 13.2% · Return on assets (EBIT) 6.8% (5-year average) · Operating margin 2.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (low confidence).
What moves the price
The share trades about 36% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 8%, RICH screens cheaper than that median.
Fair Value models
Bear770.12 ARSFair Value 1,496 ARSBull1,944 ARS
Price 1,390 ARS · Upside +7.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (150.62 ARS per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+4.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+90.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+83.0%
Start year 2020 (pandemic). Over 10 years: +75.9% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+50.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in ARS ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in ARS: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+44.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+44.7%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 26%
Compare Laboratorios Richmond SACIF with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score24 · Bottom 25%
Fair Value upside+7.6% · Above median
Profitability
Return on equity (12 months)13.2% · Above median
Return on assets0.7% · Below median
Net margin (12 months)11.0% · Above median
Operating margin (12 months)2.9% · Below median
Growth and dividend
Revenue growth (quarter YoY)−13.6% · Bottom 25%
Dividend yield (12 months)0.0% · Bottom 25%
Balance sheet
Debt / equity1.82× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Laboratorios Richmond SACIF (RICH) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 1,496 ARS versus a price of 1,390 ARS, about +8% upside (fairly valued).
What is the fair value of RICH?
Our model-based fair value for Laboratorios Richmond SACIF is 1,496 ARS (as of Nov 9, 2026), built from audited fundamentals. The current price: 1,390 ARS.
What is the quality score of RICH?
Laboratorios Richmond SACIF has a Quality Score of 24/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Laboratorios Richmond SACIF (RICH)?
Our model-based price target is the fair value of 1,496 ARS (as of Nov 9, 2026) from 14 valuation models. Cautious scenario 770.12 ARS, optimistic scenario 1,944 ARS. It is a calculation from audited fundamentals, not an analyst target.
What is the Laboratorios Richmond SACIF stock forecast for 2026?
Our models put fair value at 1,496 ARS, about +8% upside versus a price of 1,390 ARS (fairly valued). Cautious scenario 770.12 ARS, optimistic scenario 1,944 ARS. The calculation is refreshed regularly with new filings.
What is the revenue of Laboratorios Richmond SACIF (RICH)?
Laboratorios Richmond SACIF reported trailing-twelve-month revenue of about 114B ARS (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of Laboratorios Richmond SACIF (RICH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Laboratorios Richmond SACIF it is 1,496 ARS per share (as of Nov 9, 2026), against a price of 1,390 ARS. It is the blended result of 14 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Laboratorios Richmond SACIF stock overvalued or undervalued in 2026?
As of Nov 9, 2026, RICH trades below its calculated fair value: price 1,390 ARS, fair value 1,496 ARS, a gap of about +8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RICH?
No. The price is what the market pays today (1,390 ARS); the fair value is what the company's own numbers justify (1,496 ARS). For Laboratorios Richmond SACIF the two are 105.66 ARS per share apart. That gap is exactly why we show both numbers side by side.
How much is Laboratorios Richmond SACIF worth?
The market values Laboratorios Richmond SACIF at about 112B ARS (market capitalisation, as of Nov 9, 2026). Per share that is 1,390 ARS; our models calculate a fair value of 1,496 ARS per share.
What do the bullish and bearish scenarios say about RICH?
Our models span a range for Laboratorios Richmond SACIF: cautious scenario 770.12 ARS, base 1,496 ARS, optimistic 1,944 ARS per share (as of Nov 9, 2026, price 1,390 ARS). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of RICH?
Laboratorios Richmond SACIF trades at a price-to-earnings ratio of 7.3 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 1,496 ARS is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2017 to 2025), reported earnings: 51.0. Other multiples: P/B 1.2, P/S 1.0, EV/EBITDA 14.7.
How solid is the balance sheet of Laboratorios Richmond SACIF (RICH)?
Balance-sheet figures for Laboratorios Richmond SACIF (as of Nov 9, 2026): return on equity 13.2%, debt of 1.82 per unit of equity. They feed the Quality Score of 24/100, which measures business quality independently of the share price.
How far is RICH from its 52-week high?
Laboratorios Richmond SACIF trades at 1,390 ARS, about 36% below its 52-week high of 2,180 ARS and 8% above the low of 1,290 ARS (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 1,496 ARS is for.
Which stocks are comparable to Laboratorios Richmond SACIF?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Laboratorios Richmond SACIF stock attractive at the current price?
The data as of Nov 9, 2026: price 1,390 ARS, calculated fair value 1,496 ARS (+8%), Quality Score 24/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RICH calculated?
We run Laboratorios Richmond SACIF through 14 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 1,496 ARS builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Laboratorios Richmond SACIF currently trades 7% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Laboratorios Richmond SACIF (RICH)?
The closing price on Nov 6, 2026 was 1,390 ARS. Our model-based fair value is 1,496 ARS, about +8% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Laboratorios Richmond SACIF right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (770.12 ARS to 1,944 ARS) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Laboratorios Richmond SACIF
How large is the market capitalisation of Laboratorios Richmond SACIF (RICH)?
The market capitalisation of Laboratorios Richmond SACIF is 112B ARS (≈ $72.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Laboratorios Richmond SACIF (RICH)?
The price-to-sales ratio of Laboratorios Richmond SACIF is 0.98 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Laboratorios Richmond SACIF (RICH)?
Earnings per share at Laboratorios Richmond SACIF are 175.64 ARS (price ÷ EPS = P/E 7.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Laboratorios Richmond SACIF (RICH)?
The net margin of Laboratorios Richmond SACIF is 11.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Laboratorios Richmond SACIF (RICH)?
The return on equity (ROE) of Laboratorios Richmond SACIF is 13.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Laboratorios Richmond SACIF (RICH)?
On an EBIT basis the return on assets of Laboratorios Richmond SACIF is 6.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Laboratorios Richmond SACIF (RICH)?
The operating margin of Laboratorios Richmond SACIF is 2.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Laboratorios Richmond SACIF (RICH)?
Revenue at Laboratorios Richmond SACIF is growing −13.6% versus a year earlier (3y avg +90.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Laboratorios Richmond SACIF (RICH)?
Earnings per share at Laboratorios Richmond SACIF are growing +182% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Laboratorios Richmond SACIF (RICH) generate?
The free cash flow of Laboratorios Richmond SACIF is −52.5B ARS (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Laboratorios Richmond SACIF (RICH) carry?
The net debt of Laboratorios Richmond SACIF is 215B ARS (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Laboratorios Richmond SACIF in the live analysis
One click puts Laboratorios Richmond SACIF on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 9, 2026